Super-acceleration on the Brane by Energy Flow from the Bulk

We consider a brane cosmological model with energy exchange between brane and bulk. Parameterizing the energy exchange term by the scale factor and Hubble parameter, we are able to exactly solve the modified Friedmann equation on the brane. In this model, the equation of state for the effective dark energy has a transition behavior changing from $w_{de}^{eff}>-1$ to $w_{de}^{eff}<-1$, while the equation of state for the dark energy on the brane has $w>-1$. Fitting data from type Ia supernova, Sloan Digital Sky Survey and Wilkinson Microwave Anisotropy Probe, our universe is predicted now in the state of super-acceleration with $w_{de0}^{eff}=-1.21$.Comment: Revtex, 11 pages including 2 figures,v2: tpos fixed, references added, to appear in JCA

Reconstructing the properties of dark energy from recent observations

We explore the properties of dark energy from recent observational data, including the Gold Sne Ia, the baryonic acoustic oscillation peak from SDSS, the CMB shift parameter from WMAP3, the X-ray gas mass fraction in cluster and the Hubble parameter versus redshift. The $\Lambda CDM$ model with curvature and two parameterized dark energy models are studied. For the $\Lambda CDM$ model, we find that the flat universe is consistent with observations at the $1\sigma$ confidence level and a closed universe is slightly favored by these data. For two parameterized dark energy models, with the prior given on the present matter density, $\Omega_{m0}$, with $\Omega_{m0}=0.24$, $\Omega_{m0}=0.28$ and $\Omega_{m0}=0.32$, our result seems to suggest that the trend of $\Omega_{m0}$ dependence for an evolving dark energy from a combination of the observational data sets is model-dependent.Comment: 16 pages, 15 figures, To appear in JCA

Notes on interacting holographic dark energy model in a closed universe

We consider interacting holographic dark energy model in Friedmann Robertson Walker space time with positive spatial curvature and investigate the behavior of curvature parameter and dark energy density in accelerated expanding epoch. We also derive some conditions needed to cross the phantom divide line in this model.Comment: 10 pages, typos corrected, some explanations and references added and updated, accepted for publication in JCA

Gauss-Bonnet Cosmology with Induced Gravity and Non-Minimally Coupled Scalar Field on the Brane

We construct a cosmological model with non-minimally coupled scalar field on the brane, where Gauss-Bonnet and Induced Gravity effects are taken into account. This model has 5D character at both high and low energy limits but reduces to 4D gravity in intermediate scales. While induced gravity is a manifestation of the IR limit of the model, Gauss-Bonnet term and non-minimal coupling of scalar field and induced gravity are essentially related to UV limit of the scenario. We study cosmological implications of this scenario focusing on the late-time behavior of the solutions. In this setup, non-minimal coupling plays the role of an additional fine-tuning parameter that controls the initial density of predicted finite density big bang. Also, non-minimal coupling has important implication on the bouncing nature of the solutions.Comment: 33 pages, 12 figures, one table, revised and final version accepted for publication in JCA

Persistent Expression of Hepatitis C Virus Non-Structural Proteins Leads to Increased Autophagy and Mitochondrial Injury in Human Hepatoma Cells

HCV infection is a major cause of chronic liver disease and liver cancer in the United States. To address the pathogenesis caused by HCV infection, recent studies have focused on the direct cytopathic effects of individual HCV proteins, with the objective of identifying their specific roles in the overall pathogenesis. However, this approach precludes examination of the possible interactions between different HCV proteins and organelles. To obtain a better understanding of the various cytopathic effects of and cellular responses to HCV proteins, we used human hepatoma cells constitutively replicating HCV RNA encoding either the full-length polyprotein or the non-structural proteins, or cells constitutively expressing the structural protein core, to model the state of persistent HCV infection and examined the combination of various HCV proteins in cellular pathogenesis. Increased reactive oxygen species (ROS) generation in the mitochondria, mitochondrial injury and degeneration, and increased lipid accumulation were common among all HCV protein-expressing cells regardless of whether they expressed the structural or non-structural proteins. Expression of the non-structural proteins also led to increased oxidative stress in the cytosol, membrane blebbing in the endoplasmic reticulum, and accumulation of autophagocytic vacuoles. Alterations of cellular redox state, on the other hand, significantly changed the level of autophagy, suggesting a direct link between oxidative stress and HCV-mediated activation of autophagy. With the wide-spread cytopathic effects, cells with the full-length HCV polyprotein showed a modest antioxidant response and exhibited a significant increase in population doubling time and a concomitant decrease in cyclin D1. In contrast, cells expressing the non-structural proteins were able to launch a vigorous antioxidant response with up-regulation of antioxidant enzymes. The population doubling time and cyclin D1 level were also comparable to that of control cells. Finally, the cytopathic effects of core protein appeared to focus on the mitochondria without remarkable disturbances in the cytosol

Dark Energy Survey Year 1 results: cosmological constraints from galaxy clustering and weak lensing

We present cosmological results from a combined analysis of galaxy clustering and weak gravitational lensing, using 1321 deg 2 of griz imaging data from the first year of the Dark Energy Survey (DES Y1). We combine three two-point functions: (i) the cosmic shear correlation function of 26 million source galaxies in four redshift bins, (ii) the galaxy angular autocorrelation function of 650,000 luminous red galaxies in five redshift bins, and (iii) the galaxy-shear cross-correlation of luminous red galaxy positions and source galaxy shears. To demonstrate the robustness of these results, we use independent pairs of galaxy shape, photometric redshift estimation and validation, and likelihood analysis pipelines. To prevent confirmation bias, the bulk of the analysis was carried out while blind to the true results; we describe an extensive suite of systematics checks performed and passed during this blinded phase. The data are modeled in flat Λ CDM and w CDM cosmologies, marginalizing over 20 nuisance parameters, varying 6 (for Λ CDM) or 7 (for w CDM) cosmological parameters including the neutrino mass density and including the 457 × 457 element analytic covariance matrix. We find consistent cosmological results from these three two-point functions, and from their combination obtain S 8 ≡σ 8 (Ω m /0.3) 0.5 =0.783 +0.021 −0.025 and Ω m =0.264 +0.032 −0.019 for Λ CDM for w CDM, we find S 8 =0.794 +0.029 −0.027, Ω m =0.279 +0.043 −0.022, and w=−0.80 +0.20 −0.22 at 68% CL. The precision of these DES Y1 results rivals that from the Planck cosmic microwave background measurements, allowing a comparison of structure in the very early and late Universe on equal terms. Although the DES Y1 best-fit values for S 8 and Ω m are lower than the central values from Planck

Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

Background: In the treatment of type 2 diabetes, GLP-1 receptor agonists lower blood glucose concentrations, body weight, and have cardiovascular benefits. The efficacy and side effects of GLP-1 receptor agonists vary between people. Human pharmacogenomic studies of this inter-individual variation can provide both biological insight into drug action and provide biomarkers to inform clinical decision making. We therefore aimed to identify genetic variants associated with glycaemic response to GLP-1 receptor agonist treatment. Methods: In this genome-wide analysis we included adults (aged ≥18 years) with type 2 diabetes treated with GLP-1 receptor agonists with baseline HbA1c of 7% or more (53 mmol/mol) from four prospective observational cohorts (DIRECT, PRIBA, PROMASTER, and GoDARTS) and two randomised clinical trials (HARMONY phase 3 and AWARD). The primary endpoint was HbA1c reduction at 6 months after starting GLP-1 receptor agonists. We evaluated variants in GLP1R, then did a genome-wide association study and gene-based burden tests. Findings: 4571 adults were included in our analysis, of these, 3339 (73%) were White European, 449 (10%) Hispanic, 312 (7%) American Indian or Alaskan Native, and 471 (10%) were other, and around 2140 (47%) of the participants were women. Variation in HbA1c reduction with GLP-1 receptor agonists treatment was associated with rs6923761G→A (Gly168Ser) in the GLP1R (0·08% [95% CI 0·04–0·12] or 0·9 mmol/mol lower reduction in HbA1c per serine, p=6·0 × 10−5) and low frequency variants in ARRB1 (optimal sequence kernel association test p=6·7 × 10−8), largely driven by rs140226575G→A (Thr370Met; 0·25% [SE 0·06] or 2·7 mmol/mol [SE 0·7] greater HbA1c reduction per methionine, p=5·2 × 10−6). A similar effect size for the ARRB1 Thr370Met was seen in Hispanic and American Indian or Alaska Native populations who have a higher frequency of this variant (6–11%) than in White European populations. Combining these two genes identified 4% of the population who had a 30% greater reduction in HbA1c than the 9% of the population with the worse response. Interpretation: This genome-wide pharmacogenomic study of GLP-1 receptor agonists provides novel biological and clinical insights. Clinically, when genotype is routinely available at the point of prescribing, individuals with ARRB1 variants might benefit from earlier initiation of GLP-1 receptor agonists. Funding: Innovative Medicines Initiative and the Wellcome Trus

Supplement: "Localization and broadband follow-up of the gravitational-wave transient GW150914" (2016, ApJL, 826, L13)

This Supplement provides supporting material for Abbott et al. (2016a). We briefly summarize past electromagnetic (EM) follow-up efforts as well as the organization and policy of the current EM follow-up program. We compare the four probability sky maps produced for the gravitational-wave transient GW150914, and provide additional details of the EM follow-up observations that were performed in the different bands